News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVRBF) Release: Adasuve Will Now Be Launched In Sweden, Norway, Finland, And Denmark


4/30/2014 9:14:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that Adasuve now will be launched for the treatment of mild to moderate agitation of patients with schizophrenia or bipolar disorder. Medivir entered a license and distribution agreement for the commercialization of Adasuve with Ferrer in September 2013. Adasuve is a brand new inhalable treatment of agitation and is approved by EMA (European Medicines Agency) for sale in Europe.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES